ライフサイエンスコーパス: regulatory B-cell

1 st that the cell of origin of CLL might be a regulatory B cell.

2 ified and compared with previously described regulatory B cells.

3 B cells represent a unique subset of potent regulatory B cells.

4 erm remission through expansion of Tregs and regulatory B cells.

5 o molecules described as highly expressed by regulatory B cells.

6 ferentiation and restrained the expansion of regulatory B cells.

7 IL-21 can induce both plasma cells and regulatory B cells.

8 late the preferential accumulation of T2-MZP regulatory B cells.

9 at express Foxp3, suggesting an induction of regulatory B cells.

10 ism that appears to involve the induction of regulatory B cells.

11 duced expansions of cells with phenotypes of regulatory B cells.

12 -cell immune responses, and have been termed regulatory B cells.

13 unique and previously undescribed subset of regulatory B cells.

14 Regulatory B cells acquire the ability to produce IL-10

15 t data highlight the role of IL-10-producing regulatory B cells and "protective" antibodies that like

16 re associated with an increased frequency of regulatory B cells and augmented B cell-derived IL-10 pr

17 thors show that the IL-12p35 subunit induces regulatory B cells and can be used therapeutically to li

18 review, we make a case for the existence of regulatory B cells and discuss the possible developmenta

19 Regulatory B cells and myeloid-derived suppressor cells,

20 s therapeutic actions in restoring levels of regulatory B cells and suppressing neutrophil and mast c

21 Mechanisms of regulatory B cells and their cell therapy potential are

22 ts the potential relevance of transitional ("regulatory") B cells as a biomarker and therapeutic inte

23 and cells with phenotypic characteristics of regulatory B cells, as well as a long-term dominance in

24 Expression of regulatory B-cell-associated surface markers, interleuki

25 idence has demonstrated that IL-10-producing regulatory B cells (B(regs)) are specialized to suppress

26 Regulatory B cells (B-reg) produce IL-10 and suppress in

27 ove the acute expansion of a small subset of regulatory B cells (B10 cells) that potently suppress in

28 Human and mouse regulatory B cells (B10 cells) with the ability to expre

29 of cGVHD and support future investigation of regulatory B cell-based therapy in the treatment of this

30 Impaired regulatory B cell (Breg) responses are associated with s

31 Regulatory B cells (Breg cells) differentiate in respons

32 late T-cell immune responses, and are termed regulatory B cells (Breg).

33 at a similar process may operate to modulate regulatory B cells (Breg).

34 We identified regulatory B cells (Bregs) and regulatory myeloid cells

35 A subset of regulatory B cells (Bregs) in mice negatively regulate T

36 Regulatory B cells (Bregs) modulate immune responses pre

37 Here, we evaluated the influence of regulatory B cells (Bregs) on T-cell cytokines in vitro

38 al group of interleukin-10 (IL-10)-producing regulatory B cells (Bregs) that negatively regulate T-ce

39 roducing B cells represent a major subset of regulatory B cells (Bregs) that suppress autoimmune and

40 oth cytokine expression and number of TIM-1+ regulatory B cells (Bregs) were induced by TIM-1-specifi

41 estigation, elevated CD19(+) CD24(+) CD38(+) regulatory B cells (Bregs) were observed in PBMCs of inv

42 One functional B cell subset, regulatory B cells (Bregs), has recently been shown to c

43 the existence of a subset of B lymphocytes, regulatory B cells (Bregs), which modulate immune functi

44 in domain (Tim)-1 identifies IL-10-producing regulatory B cells (Bregs).

45 d a profound defect in IL-10 production from regulatory B cells (Bregs).

46 Interleukin 10 (IL-10)-producing B cells (regulatory B cells [Bregs]) regulate autoimmunity in mic

47 tially suppressive cells, including not only regulatory B cells but also Tregs.

48 strate that IFN-beta therapy requires immune-regulatory B cells by showing that B cell-deficient mice

49 ltogether, these data indicate a compromised regulatory B-cell compartment as an additional defect in

50 Regulatory B cells control inflammation and autoimmunity

51 s through the induction of immunosuppressive regulatory B cells, designated tBregs.

52 Recent studies indicate that regulatory B cells develop in several murine models of c

53 e demonstrated the presence in the spleen of regulatory B cells enriched in the CD24(int)CD38(+)CD27(

54 ssed the putative generation of anti-colitic regulatory B cells following H. diminuta infection.

55 CD19(+), CD5(-), CD1d(-), IgD(hi) regulatory B cells from healthy controls produced IL-10

56 characterization of the mechanisms by which regulatory B cells function has led to the identificatio

57 Granzyme B-expressing regulatory B cells (GraB cells) cells from HIV patients

58 The immunosuppressive function of regulatory B cells has been shown in several murine mode

59 Production of IL-10 by regulatory B cells has been shown to modulate the severi

60 A novel subset of human regulatory B-cells has recently been described.

61 Regulatory B cells have largely been reported as B cells

62 Unlike splenic regulatory B cells, however, these TDLN B cells did not

63 ssed by a large majority of IL-10-expressing regulatory B cells in all major B cell subpopulations, i

64 In conclusion, GraB cells represent potent regulatory B cells in humans that are phenotypically and

65 he importance of Itga4 for the generation of regulatory B cells in peripheral immune organs and their

66 We investigated the role of IL-10 and regulatory B cells in the pathogenesis of CHB.

67 s highlighting a protective role of IL-10(+) regulatory B cells in this setting.

68 y and inflammation are controlled in part by regulatory B cells, including a recently identified IL-1

69 Immune suppression by regulatory T cells and regulatory B cells is a critical mechanism to limit exce

70 and humans, a rare, but specific, subset of regulatory B cells is functionally characterized by its

71 d to the identification of a novel subset of regulatory B cells known as B10 cells, which regulate im

72 pe in stroke and suggest that enhancement of regulatory B cells might have application as a novel the

73 molecule (TIM)-1 broadly identifies IL-10(+) regulatory B cells, no similar markers for Be1 cells hav

74 Neither regulatory B cells nor tolerogenic dendritic cells contr

75 x 10(9) cells/L (P = .001), indicating that regulatory B cells of patients with ITP are functionally

76 1 expression and high in vivo frequencies of regulatory B cells overexpressing the serine protease gr

77 A specific deficit in regulatory B cells participates to more severe allergic

78 These data suggest the existence of a regulatory B-cell population that promotes tolerance via

79 FN-beta treatment increases transitional and regulatory B cell populations, as well as IL-10 secretio

80 ften have features of the recently described regulatory B cells producing immunosuppressive IL-10.

81 rived regulatory cell populations, including regulatory B cells, regulatory macrophages, tolerogenic

82 se or after differentiating into more mature regulatory B cells remain to be characterized.

83 d functional overlap between these cells and regulatory B cells remains controversial.

84 IgD(hi) regulatory B cells represent a novel regulatory B cell t

85 ed after episodes of inflammation, or if the regulatory B-cell response is subverted.

86 ition, potentially protective CD1d(hi)CD5(+) regulatory B cells show resistance to depletion, and mye

87 In addition, recent studies of regulatory B cells strongly suggest that Tregs may not h

88 and a rare IL-10-producing CD1d(high)CD5(+) regulatory B cell subset (B10 cells) have been identifie

89 pletion of a rare IL-10-producing CD1dhiCD5+ regulatory B cell subset (B10 cells), since the adoptive

90 paralleled depletion of the IL-10-producing regulatory B cell subset called B10 cells.

91 For clarity, this regulatory B cell subset has been labeled as B10 cells,

92 The spleen regulatory B cell subset with the functional capacity to

93 dies have identified a novel IL-12-producing regulatory B-cell subset that develops under Th2-mediate

94 However, specific regulatory B cell subsets recently were identified that

95 B cells, there is also mounting evidence for regulatory B cell subsets that may play a protective rol

96 kade did not change other previously defined regulatory B-cell subsets (Breg), including CD5CD1d Breg

97 In allergy, some regulatory B-cell subsets producing IL-10 have been rece

98 IL-10-producing regulatory B cells suppress immune responses, and lack o

99 be abrogated by inactivation of tumor-evoked regulatory B cells (tBreg).

100 We reported previously that tumor-evoked regulatory B cells (tBregs) play an essential role in br

101 IgD(hi) regulatory B cells represent a novel regulatory B cell that may precipitate T cell exhaustion

102 Regulatory B cells that are functionally defined by thei

103 To investigate the potential contribution of regulatory B cells, their frequency was measured directl

104 ciliated cells, it activates human neonatal regulatory B cells, thereby inhibiting immunological res

105 ILC3s and regulatory B cells were in close connection with each ot

106 Regulatory B cells were not required for induction of to

107 Tonsillar ILC3s and regulatory B cells were visualized with immunofluorescen

108 sets, including B effector 1 (Be1) cells and regulatory B cells, which can promote or inhibit immune

109 e response through the generation of CD19(+) regulatory B cells, which in turn are able to influence

110 of cognate B cells into disease-suppressing regulatory B cells, without compromising systemic immuni